Evidence map›Paper›PMID 42387290›Full record

ArticleDiabetes, obesity & metabolism2026

Tirzepatide Is Associated With Improved Metabolic Outcomes in People With Type 1 Diabetes and Overweight or Obesity: A Retrospective Cohort Study.

Amanda R Purcell, Matilda S G Longfield, Natassia Rodrigo, Sarah J Glastras

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Amanda R PurcellFaculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.ORCID https://orcid.org/0009-0003-5728-6054
Matilda S G LongfieldFaculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0002-3795-2254
Natassia RodrigoFaculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
Sarah J GlastrasFaculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.

Funding

Breakthrough T1D PhD Top-Up ScholarshipUniversity of Sydney Postgraduate Award, Australian Centre for Accelerating Diabetes Innovations PhD Grant
6 · The paper itself

Abstract

aimsTo evaluate the effect of tirzepatide on body weight, glycaemic control, insulin requirements, continuous glucose monitoring (CGM) metrics and cardiorenal parameters in adults with Type 1 diabetes (T1D) and overweight or obesity. MATERIALS AND

methodsIn this retrospective matched cohort study, adults with T1D, BMI ≥ 27 kg/m

resultsMean follow-up duration in the tirzepatide and control groups were 28 and 31 weeks, respectively. The most common dose of tirzepatide was 5 mg/week (52.2% participants). Compared with controls, tirzepatide was associated with greater reductions in body weight (-10.01% ± 4.74% vs. +0.69% ± 3.77%, adj-p < 0.0001) and total daily insulin dose (-21.82 ± 16.30 vs. +5.62 ± 11.63 U/day; adj-p = 0.002). From baseline to end-of-study, tirzepatide was associated with a reduction in glucose management indicator, glucose SD and daily carbohydrate intake. Other CGM, blood pressure, lipid, hepatic and renal outcomes did not differ.

conclusionsIn adults with T1D and overweight or obesity, adjunctive tirzepatide treatment was associated with clinically meaningful reductions in percentage body weight and insulin requirements. Larger prospective studies are needed to confirm efficacy, ensure safety and assess broader cardiometabolic effects.

Indexed as

Diabetes Mellitus, Type 1Hypoglycemic AgentsObesityOverweightTirzepatideAdultBlood GlucoseContinuous Glucose MonitoringFemaleGlycated HemoglobinGlycemic ControlHumansInsulinMaleMiddle AgedRetrospective StudiesBlood GlucoseGlycated HemoglobinHypoglycemic AgentsInsulinTirzepatideantiobesity drugcontinuous glucose monitoring (CGM)database researchGLP‐1 analogueincretin therapyreal‐world evidence

Identifiers

PMID42387290
PMCPMC13448848

What Socratic holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.